Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04472611 · ClinicalTrials.gov registry record · Phase 3

Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial

A Phase 3 study, sponsored by Yale University.

Completed
Registry status
Phase 3
Development phase
250
Enrollment target

NCT04472611: Completed Phase 3 study, sponsored by Yale University.

NCT04472611 is a Phase 3 study that has completed, run by Yale University. The registered enrollment target is 250 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04472611, a Phase 3 study, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 3
Development phase
250 participants
Enrollment target

Study Summary

This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2

Primary Outcome

As defined by World Health Organization Ordinal Scale, which ranges from 1 to 8. Severity of COVID measured by WHO Scores 5-8: Defined as 5= Hospitalized requiring including CPAP, face mask, high flow nasal cannula (Excludes regular nasal cannula), 6= Hospitalized requiring intubation and mechanical ventilation, 7= Hospitalized requiring mechanical ventilation and additional organ support (vasopressors, renal replacement therapy, ECMO), 8= Death. Data presented is for Max WHO scores 5-8, indicat

Interventions

  • DRUG Standard of Care (SOC) and Colchicine+Rosuvastatin

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2020-10-30
Est. Completion 2022-03-30
Phase Phase 3
Yale University

1,492 total trials

What the finished NCT04472611 record still lists

NCT04472611 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).

The record links to 0 conditions, and to 1 intervention - of which Standard of Care (SOC) and Colchicine+Rosuvastatin is the first listed.

NCT04472611 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04472611 about?

NCT04472611 is a clinical study titled "Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial". This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2

What is the current status of trial NCT04472611?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2020-10-30. Estimated completion is 2022-03-30.

What interventions are being tested in trial NCT04472611?

The interventions under investigation include: Standard of Care (SOC) and Colchicine+Rosuvastatin (DRUG).

Who is sponsoring clinical trial NCT04472611?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04472611's enrollment target sits among peer trials

250 1249th of 2000 higher than 735 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04472611, the US trial registry maintained by the National Library of Medicine. NCT04472611 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.